Immunization, Hib3 in North America
North America: Immunization, Hib3 was 91.8% in 2024. ▲ Rising
Immunization, Hib3 in North America, 1990–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
North America recorded 91.8% for immunization, hib3 in 2024.
The figure is down 1.1% over ten years.
Over the whole period, immunization, hib3 in North America peaked at 93.9% in 2005 and was at its lowest, 0.0%, in 1990.
North America ranks 10th of 43 groups on this measure, in the top quarter.
The long-run direction has been consistently rising across the 35 years of available data.
Immunization, Hib3 in North America, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1990 | 0.0% | — |
| 1991 | 0.0% | — |
| 1992 | 0.0% | — |
| 1993 | 0.0% | — |
| 1994 | 0.0% | — |
| 1995 | 82.7% | — |
| 1996 | 90.4% | +9.3% |
| 1997 | 92.5% | +2.3% |
| 1998 | 92.6% | +0.1% |
| 1999 | 93.5% | +1.0% |
| 2000 | 92.6% | -1.0% |
| 2001 | 92.6% | +0.0% |
| 2002 | 92.6% | +0.0% |
| 2003 | 93.5% | +1.0% |
| 2004 | 93.8% | +0.3% |
| 2005 | 93.9% | +0.2% |
| 2006 | 93.2% | -0.8% |
| 2007 | 93.0% | -0.2% |
| 2008 | 91.1% | -2.1% |
| 2009 | 84.6% | -7.1% |
| 2010 | 90.0% | +6.4% |
| 2011 | 93.6% | +4.0% |
| 2012 | 92.7% | -0.9% |
| 2013 | 92.8% | +0.1% |
| 2014 | 92.8% | -0.0% |
| 2015 | 92.8% | +0.0% |
| 2016 | 92.8% | +0.0% |
| 2017 | 91.9% | -1.0% |
| 2018 | 91.9% | -0.0% |
| 2019 | 91.1% | -0.9% |
| 2020 | 91.1% | +0.0% |
| 2021 | 91.1% | +0.0% |
| 2022 | 91.8% | +0.8% |
| 2023 | 91.8% | +0.0% |
| 2024 | 91.8% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 45.2% | 0.0% | 93.5% | 10 |
| 2000s | 92.1% | 84.6% | 93.9% | 10 |
| 2010s | 92.3% | 90.0% | 93.6% | 10 |
| 2020s | 91.5% | 91.1% | 91.8% | 5 |
More health data for North America
- Population ages 60-64, female, per capita 0.0315 units per person (2025)
- Population ages 65-69, female, per capita 0.0299 units per person (2025)
- Population ages 65-69, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 20-24, male, per capita 0.0339 units per person (2025)
- Population ages 65-69, female, annual growth rate 1.32 % change on previous year (2025)
- Population ages 60-64, male, per capita 0.0311 units per person (2025)
- Population ages 60-64, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 25-29, female, annual growth rate 0.2706 % change on previous year (2025)
- Population ages 60-64, male, annual growth rate -0.5906 % change on previous year (2025)
- Population ages 55-59, male, annual growth rate -0.5946 % change on previous year (2025)
Frequently asked questions
- What is immunization, hib3 in North America?
- Immunization, hib3 in North America was 91.8% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in North America?
- The highest recorded value was 93.9% in 2005.
- What is the lowest immunization, hib3 recorded in North America?
- The lowest recorded value was 0.0% in 1990.
- How does North America rank for immunization, hib3?
- North America ranks 10th out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in North America?
- Over the last ten years it is down 1.1%. The long-run trend across the full record is rising.
- Where does this North America data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.